Balchem Management

How has Ted Harris's remuneration changed compared to Balchem's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	US$109m
Sep 30 2023	n/a	n/a	US$103m
Jun 30 2023	n/a	n/a	US$99m
Mar 31 2023	n/a	n/a	US$99m
Dec 31 2022	US$12m	US$1m	US$105m
Sep 30 2022	n/a	n/a	US$109m
Jun 30 2022	n/a	n/a	US$109m
Mar 31 2022	n/a	n/a	US$102m
Dec 31 2021	US$6m	US$1m	US$96m
Sep 30 2021	n/a	n/a	US$93m
Jun 30 2021	n/a	n/a	US$90m
Mar 31 2021	n/a	n/a	US$88m
Dec 31 2020	US$5m	US$1m	US$85m
Sep 30 2020	n/a	n/a	US$83m
Jun 30 2020	n/a	n/a	US$82m
Mar 31 2020	n/a	n/a	US$81m
Dec 31 2019	US$4m	US$915k	US$80m
Sep 30 2019	n/a	n/a	US$80m
Jun 30 2019	n/a	n/a	US$78m
Mar 31 2019	n/a	n/a	US$78m
Dec 31 2018	US$3m	US$800k	US$79m
Sep 30 2018	n/a	n/a	US$100m
Jun 30 2018	n/a	n/a	US$97m
Mar 31 2018	n/a	n/a	US$94m
Dec 31 2017	US$2m	US$700k	US$90m

Compensation vs Market: Ted's total compensation ($USD11.95M) is above average for companies of similar size in the US market ($USD6.57M).

Compensation vs Earnings: Ted's compensation has increased by more than 20% in the past year.

CEO

Ted Harris (58 yo)

9yrs

Tenure

US$11,948,265

Compensation

Mr. Theodore L. Harris, also known as Ted, has been the Chief Executive Officer and President at Balchem Corporation since April 28, 2015. He serves as an Independent Director of Pentair Plc since April 30...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Theodore Harris	Chairman	9yrs	US$11.95m	0.21% $ 9.6m
Carl Bengtsson	Executive VP	5.2yrs	US$1.67m	0.061% $ 2.9m
Hatsuki Miyata	Executive VP	1.8yrs	US$1.15m	0.018% $ 820.6k
Jonathan Griffin	Senior Vice President of Corporate Development	less than a year	US$1.01m	0.039% $ 1.8m
Martin Reid	Senior VP & Chief Supply Chain Officer	3.3yrs	US$1.10m	0.020% $ 943.7k
William Backus	VP & Chief Accounting Officer	12.8yrs	US$960.42k	0.018% $ 858.0k
Michael Sestrick	Senior VP & CTO	1.6yrs	no data	0.021% $ 977.4k
M. Tignor	Senior VP & Chief Human Resources Officer	2.2yrs	no data	0.026% $ 1.2m
Frederic Boned	Senior VP and GM of Human Nutrition & Health	1.4yrs	no data	0.016% $ 771.9k
Job L. Gunsteren	Senior VP & GM of Specialty Products	1.6yrs	no data	no data

2.0yrs

Average Tenure

47yo

Average Age

Experienced Management: BCPC's management team is not considered experienced ( 2 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Theodore Harris	Chairman	9yrs	US$11.95m	0.21% $ 9.6m
Daniel Knutson	Independent Director	6.2yrs	US$220.30k	0.016% $ 732.6k
David Fischer	Independent Director	13.6yrs	US$205.80k	0.043% $ 2.0m
Matthew Wineinger	Lead Independent Director	8.6yrs	US$216.46k	0.019% $ 894.1k
Olivier Rigaud	Independent Director	less than a year	no data	0.0017% $ 78.2k
Joyce Lee	Independent Director	4.6yrs	US$205.80k	0.0086% $ 402.6k
Kathleen Fish	Independent Director	2.8yrs	US$204.80k	0.0049% $ 228.9k
Monica Vicente	Independent Director	less than a year	no data	0.0017% $ 78.2k

5.4yrs

Average Tenure

58.5yo

Average Age

Experienced Board: BCPC's board of directors are considered experienced (5.4 years average tenure).

Balchem Management

Management criteria checks 1/4

Key information

Recent management updates

Chairman recently sold US$4.6m worth of stock

Chairman notifies of intention to sell stock

Independent Director recently sold US$500k worth of stock

Balchem Corporation Announces Board Appointments, Effective as of September 6, 2023

Senior VP & CTO recently sold US$300k worth of stock

Independent Director recently sold US$381k worth of stock

Recent updates

Balchem Corporation to Report Q1, 2024 Results on May 03, 2024

Balchem Corporation's (NASDAQ:BCPC) Popularity With Investors Is Clear

Is Balchem Corporation (NASDAQ:BCPC) Expensive For A Reason? A Look At Its Intrinsic Value

Chairman recently sold US$4.6m worth of stock

Chairman notifies of intention to sell stock

Balchem: Potential Turnaround Is In The Price

These 4 Measures Indicate That Balchem (NASDAQ:BCPC) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS misses analyst expectations

Now 21% overvalued after recent price rise

Balchem Corporation to Report Q4, 2023 Results on Feb 16, 2024

Returns On Capital At Balchem (NASDAQ:BCPC) Have Stalled

Upcoming dividend of US$0.79 per share at 0.5% yield

Balchem Corporation's (NASDAQ:BCPC) P/E Is On The Mark

Balchem Corporation Announces Dividend, Payable on January 19, 2024

Estimating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)

Price target decreased by 8.4% to US$145

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Balchem (NASDAQ:BCPC) Has A Pretty Healthy Balance Sheet

Balchem Corporation to Report Q3, 2023 Results on Oct 27, 2023

Independent Director recently sold US$500k worth of stock

The Returns At Balchem (NASDAQ:BCPC) Aren't Growing

Balchem Corporation Announces Board Appointments, Effective as of September 6, 2023

A Look At The Intrinsic Value Of Balchem Corporation (NASDAQ:BCPC)

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Balchem (NASDAQ:BCPC) A Risky Investment?

Balchem Corporation to Report Q2, 2023 Results on Jul 28, 2023

Some Investors May Be Worried About Balchem's (NASDAQ:BCPC) Returns On Capital

Calculating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)

Senior VP & CTO recently sold US$300k worth of stock

First quarter 2023 earnings: EPS exceeds analyst expectations

Do Balchem's (NASDAQ:BCPC) Earnings Warrant Your Attention?

Independent Director recently sold US$381k worth of stock

We Think Balchem (NASDAQ:BCPC) Can Stay On Top Of Its Debt

Full year 2022 earnings: EPS misses analyst expectations

Balchem Corporation to Report Q4, 2022 Results on Feb 24, 2023

Balchem (NASDAQ:BCPC) Hasn't Managed To Accelerate Its Returns

Here's Why We Think Balchem (NASDAQ:BCPC) Is Well Worth Watching

Upcoming dividend of US$0.71 per share

Is Balchem (NASDAQ:BCPC) A Risky Investment?

Balchem Corporation Announces Dividend, Payable on January 20, 2023

Balchem Corporation (NASDAQ:BCPC) Shares Could Be 26% Above Their Intrinsic Value Estimate

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Balchem Corporation to Report Q3, 2022 Results on Nov 04, 2022

Insufficient new directors

James C. Hyde, Senior Vice President and General Manager, Human Nutrition & Health, Notifies Balchem Corporation His Intent to Retire from His Role

Here's What To Make Of Balchem's (NASDAQ:BCPC) Decelerating Rates Of Return

Balchem: Acquisitions And Cost Pressures Draw Attention

Balchem (NASDAQ:BCPC) Seems To Use Debt Rather Sparingly

Balchem to acquire Cardinal Associates or Bergstrom Nutrition

Is Balchem Corporation (NASDAQ:BCPC) Worth US$138 Based On Its Intrinsic Value?

Should You Be Adding Balchem (NASDAQ:BCPC) To Your Watchlist Today?

Insider recently sold US$175k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Balchem Q2 2022 Earnings Preview

Balchem Corporation to Report Q2, 2022 Results on Jul 29, 2022

Balchem: On The M&A Road Again

Balchem Corporation (NasdaqGS:BCPC) completed the acquisition of Kappa Bioscience AS from Verdane Edda managed by Verdane and others on June 21, 2022.

Balchem Corporation (NasdaqGS:BCPC) entered into an agreement to acquire Kappa Bioscience AS from Verdane Edda managed by Verdane and others.

Balchem Corporation Announces Resignation of Mark Stach as Company Secretary

Balchem: A New Growth Stage Is Just Beginning

Slowing Rates Of Return At Balchem (NASDAQ:BCPC) Leave Little Room For Excitement

Balchem Corporation's (NASDAQ:BCPC) Intrinsic Value Is Potentially 17% Below Its Share Price

Does Balchem (NASDAQ:BCPC) Deserve A Spot On Your Watchlist?

Balchem Corporation, Annual General Meeting, Jun 23, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Balchem Corporation to Report Q1, 2022 Results on Apr 29, 2022

Does Balchem (NASDAQ:BCPC) Have A Healthy Balance Sheet?